drugset

drugset / Trial / NCT03986528

Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT03986528 ↗

Phase 4 Unknown 334 enrolled Jie Li Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences · collab Ministry of Science and Technology of the People´s Republic of China · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Kanglaite Injection for advanced non-small cell lung cancer(NSCLC).

Timeline

Start: 2019-08-28
Primary completion: 2022-03-31
Completion: 2022-05-31

Publications

Gao R, Zhang Y, Hou W, Li J, Zhu G, Zhang X, Xu B, Wu Z, Wang H. Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial. Trials. 2021 Mar 17;22(1):214. doi: 10.1186/s13063-021-05169-w.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Kanglaite Injection	Unknown	200 ml	Intravenous
Comparator	Carboplatin	Small molecule	6 unknown	Intravenous
Comparator	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Comparator	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Comparator	Paclitaxel	Small molecule	135 mg/m2	Intravenous
Comparator	Pemetrexed	Small molecule	500 mg/m2	Intravenous

Indications